Dang, Julie

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine

Glioma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 593

An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway

Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A. N., Soto, H., Zhu, S., et al. (2011) · Cancer Discovery

Cancer, Lipids, and MetabolismGlioma Diagnosis and Treatment

Cited by 452

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

Guo, D., Prins, R. M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K. Y., Huang, T. T., Akhavan, D., Hock, M. B., et al. (2009) · Science Signaling

Cancer, Lipids, and MetabolismGlioma Diagnosis and Treatment

Cited by 351

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

Guo, D., Hildebrandt, I. J., Prins, R. M., Soto, H., Mazzotta, M. M., Dang, J., Czernin, J., Shyy, J. Y.-J., Watson, A. D., Phelps, M., et al. (2009) · Proceedings of the National Academy of Sciences

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 232